Stockscreener 앱 받기
2.62
3.68%
-0.10
전일 마감가:
$2.72
열려 있는:
$2.56
하루 거래량:
55,910
Relative Volume:
1.60
시가총액:
$47.71M
수익:
$-41,600
순이익/손실:
$-9.46M
주가수익비율:
-0.0905
EPS:
-28.9457
순현금흐름:
$-8.70M
1주 성능:
-15.89%
1개월 성능:
-31.95%
6개월 성능:
-34.01%
1년 성능:
-45.76%
1일 변동 폭
$2.35
$2.955
1주일 범위
$2.35
$3.40
52주 변동 폭
$2.35
$5.8922
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
Compare ATHE vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
2.62 | 47.71M | -41,600 | -9.46M | -8.70M | -28.95 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-11 | 개시 | Craig Hallum | Buy |
| 2026-06-16 | 재개 | Ladenburg Thalmann | Buy |
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Immutep Limited (IMMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alterity Therapeutics (ATHE) ADR Edges Up 1.43% to $3.91, Holding Above $3.71 SupportAdvance Decline Line - https://www.dars.gov.et/
Alterity Therapeutics at Cantor healthcare conference: phase iii path sharpens By Investing.com - Investing.com South Africa
Alterity Therapeutics at Cantor healthcare conference: phase iii path sharpens - Investing.com
ALTERITY THERAPEUTICS LTD (NASDAQ: ATHE) Director Acquires 47,620 Shares at $0.50 Each - Kalkine Media
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Alterity Therapeutics Director David Stamler's Listed Options Expire on 31 August 2026 - Kalkine
Alterity Therapeutics Reports A$17.6M in R&D Expenses for Fiscal Year Ending June 30, 2026 - Kalkine Media
Alterity Therapeutics (ATHE) Holds Steady at $4.51 as Shares Consolidate Within a Tight Trading RangeATR Trailing Stop - careplusvn.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Alterity (ATHE) Chart: Closes 4.94% Higher at $4.67; Technical View: the Near-Term Reference Band Stretches From $4.44 to $4.90 in the Latest SessionFibonacci Entry Signals - dars.gov.et
Alterity (ATHE) Chart: Closes 4.94% Higher at $4.67; Technical View: the Near-Term Reference Band Stretches From $4.44 to $4.90 in the Latest SessionDip Buy Trade - careplusvn.com
Alterity (ATHE): Advances 4.94% to $4.67 for the Current Session; Next Session: the Supplied Trading Band Runs From $4.44 to $4.90 in Latest TradingHigh Beta Stocks - dars.gov.et
Alterity (ATHE): Advances 4.94% to $4.67 for the Current Session; Next Session: the Supplied Trading Band Runs From $4.44 to $4.90 in Latest TradingNAAIM Leverage - dars.gov.et
Alterity Therapeutics (ATHE) Declines 4.6% to $4.57 as Shares Test Key SupportDelta Hedging - careplusvn.com
Alterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range - Kalkine
Clinuvel Pharmaceuticals (ASX:CUV) Makes U.S. Pivot With Nasdaq Uplisting and Headquarters Shift Plan - Kalkine
Alterity Therapeutics Secures Key US Patent for Lead Asset - Sahm
Alterity Therapeutics at Canaccord conference: phase III path in focus By Investing.com - Investing.com India
Alterity Therapeutics at Canaccord conference: phase III path in focus - Investing.com
Craig-Hallum initiates Alterity Therapeutics stock coverage with buy rating - Investing.com
Acrux Ltd (ASX:ACR) Share Price Update: Trading Snapshot for 11 August 2026 - Kalkine
Alterity Therapeutics (ATHE) Climbs 3.41% as Shares Advance Toward $4.94 ResistanceLow Beta Factor - dars.gov.et
Alterity Therapeutics (ATHE) Climbs 3.41% as Shares Advance Toward $4.94 ResistancePut Dominated - careplusvn.com
Alterity Therapeutics (ATHE) Gains 1.24% to $4.5, Holding Above Key SupportFibonacci Fan - vinanet.vn
Alterity Therapeutics (ATHE) Gains 1.24% to $4.5, Holding Above Key SupportSentiment Divergence - dars.gov.et
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update - Yahoo Finance
PRNAF SEC FilingsALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Forms - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ATHE News | ALTERITY THERAPEUTICS-ADR (NASDAQ:ATHE) - ChartMill
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Jones Trading initiates Alterity Therapeutics stock with buy rating - Investing.com
Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE) - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Sahm
Insights: Alterity Therapeutics Ltd (ASX:ATHDA) - smallcaps.com.au
ATHEAlterity Therapeutics Ltd ADR Short Interest - Finviz
ATHEAlterity Therapeutics Ltd ADR Volatility & Greeks - Finviz
Weiss Ratings Stock Recommendations & Analyst Ratings 2026 - marketbeat.com
Alterity Therapeutics (NASDAQ: ATHE) sets vote on 50:1 consolidation and large option, incentive issuances - Stock Titan
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Alterity Therapeutics appoints Ann Cunningham to board - Investing.com
Alterity Therapeutics appoints Ann Cunningham to board By Investing.com - Investing.com India
Nerves settle as oil drops - The Cairns Post
Nerves settle as oil drops - Geelong Advertiser
Nerves settle as oil drops - Daily Telegraph Sydney
Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 MSA Program - smallcaps.com.au
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
알테리티 테라퓨틱스 (ATHE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):